Veracyte (VCYT) | Financial Analysis & Statements
Veracyte Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
140.6M
Gross Profit
102.0M
72.51%
Operating Income
39.9M
28.38%
Net Income
41.1M
29.26%
EPS (Diluted)
$0.51
Balance Sheet Metrics
Total Assets
1.4B
Total Liabilities
96.4M
Shareholders Equity
1.3B
Debt to Equity
0.07
Cash Flow Metrics
Operating Cash Flow
46.7M
Free Cash Flow
48.8M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Veracyte Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 517.1M | 445.8M | 361.1M | 296.5M | 219.5M |
| Cost of Goods Sold | 154.6M | 147.6M | 112.9M | 101.6M | 74.4M |
| Gross Profit | 362.5M | 298.1M | 248.1M | 195.0M | 145.1M |
| Gross Margin % | 70.1% | 66.9% | 68.7% | 65.7% | 66.1% |
| Operating Expenses | |||||
| Research & Development | 70.8M | 69.3M | 57.3M | 40.6M | 29.8M |
| Selling, General & Administrative | 210.9M | 206.0M | 184.2M | 168.5M | 181.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 281.8M | 275.3M | 241.5M | 209.1M | 211.0M |
| Operating Income | 78.3M | 20.0M | -16.9M | -35.3M | -80.4M |
| Operating Margin % | 15.1% | 4.5% | -4.7% | -11.9% | -36.6% |
| Non-Operating Items | |||||
| Interest Income | 12.7M | 11.2M | 7.3M | 2.0M | 135.0K |
| Interest Expense | 1.0K | 2.0K | 15.0K | 198.0K | 241.0K |
| Other Non-Operating Income | -22.8M | -5.4M | -67.1M | -2.9M | -1.2M |
| Pre-tax Income | 68.2M | 25.7M | -76.6M | -36.4M | -81.6M |
| Income Tax | 1.8M | 1.6M | -2.2M | 133.0K | -6.1M |
| Effective Tax Rate % | 2.7% | 6.2% | 0.0% | 0.0% | 0.0% |
| Net Income | 66.4M | 24.1M | -74.4M | -36.6M | -75.6M |
| Net Margin % | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% |
| Key Metrics | |||||
| EBITDA | 112.9M | 54.6M | 18.2M | -7.2M | -60.7M |
| EPS (Basic) | $0.84 | $0.32 | $-1.02 | $-0.51 | $-1.11 |
| EPS (Diluted) | $0.82 | $0.31 | $-1.02 | $-0.51 | $-1.11 |
| Basic Shares Outstanding | 78584291 | 76484759 | 72644487 | 71549204 | 67890328 |
| Diluted Shares Outstanding | 78584291 | 76484759 | 72644487 | 71549204 | 67890328 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Veracyte Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 362.6M | 239.1M | 216.5M | 154.2M | 173.2M |
| Short-term Investments | 50.3M | 50.4M | 0 | 24.6M | 4.0M |
| Accounts Receivable | 44.7M | 46.5M | 40.4M | 44.0M | 41.5M |
| Inventory | 20.5M | 21.8M | 16.1M | 14.3M | 11.2M |
| Other Current Assets | 10.3M | 14.6M | 12.7M | 11.5M | 13.3M |
| Total Current Assets | 488.4M | 372.3M | 285.6M | 248.6M | 243.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 73.3M | 81.9M | 37.1M | 34.3M | 33.6M |
| Goodwill | 1.6B | 1.6B | 1.5B | 1.6B | 1.6B |
| Intangible Assets | 89.1M | 102.3M | 88.6M | 174.9M | 202.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 2.6M | 8.5M | 6.8M | 6.2M | 2.9M |
| Total Non-Current Assets | 917.6M | 927.8M | 829.3M | 907.8M | 944.7M |
| Total Assets | 1.4B | 1.3B | 1.1B | 1.2B | 1.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 4.6M | 8.6M | 12.9M | 11.9M | 12.4M |
| Short-term Debt | 4.1M | 7.5M | 5.1M | 4.1M | 4.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.3M | 17.0M | 2.8M | 6.2M | 2.9M |
| Total Current Liabilities | 59.9M | 78.6M | 61.2M | 62.6M | 64.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 35.6M | 43.2M | 7.5M | 10.6M | 14.1M |
| Deferred Tax Liabilities | 646.0K | 1.2M | 734.0K | 4.5M | 5.6M |
| Other Non-Current Liabilities | 257.0K | 972.0K | 1.3M | 3.4M | 7.1M |
| Total Non-Current Liabilities | 36.5M | 45.4M | 9.6M | 18.6M | 27.2M |
| Total Liabilities | 96.4M | 124.1M | 70.8M | 81.2M | 91.3M |
| Equity | |||||
| Common Stock | 79.0K | 78.0K | 73.0K | 72.0K | 71.0K |
| Retained Earnings | -377.6M | -444.0M | -468.1M | -393.7M | -357.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.3B | 1.2B | 1.0B | 1.1B | 1.1B |
| Key Metrics | |||||
| Total Debt | 39.7M | 50.7M | 12.6M | 14.7M | 18.9M |
| Working Capital | 428.4M | 293.6M | 224.4M | 186.0M | 179.0M |
Balance Sheet Composition
Veracyte Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 66.4M | 24.1M | -74.4M | -36.6M | -75.6M |
| Depreciation & Amortization | 21.4M | 23.5M | 27.2M | 25.9M | 19.6M |
| Stock-Based Compensation | 43.6M | 36.2M | 33.1M | 26.7M | 22.5M |
| Working Capital Changes | -6.6M | -23.6M | -3.0M | -13.9M | -6.9M |
| Operating Cash Flow | 111.9M | 67.2M | -22.2M | 6.0M | -43.9M |
| Investing Activities | |||||
| Capital Expenditures | -9.7M | -11.3M | -10.0M | -8.5M | -5.4M |
| Acquisitions | -2.8M | 5.0M | 0 | 0 | -736.8M |
| Investment Purchases | -150.0M | -50.0M | -19.7M | -33.5M | 0 |
| Investment Sales | 153.3M | 0 | 44.8M | 12.7M | 3.0M |
| Investing Cash Flow | -9.2M | -56.3M | 15.1M | -29.4M | -739.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | 0 | 0 | -1.3M | 0 |
| Financing Cash Flow | -18.3M | -15.1M | -6.7M | -4.4M | 584.8M |
| Free Cash Flow | 126.6M | 63.8M | 34.3M | -1.0M | -37.0M |
| Net Change in Cash | 84.4M | -4.2M | -13.8M | -27.8M | -198.4M |
Cash Flow Trend
Veracyte Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
40.43
Forward P/E
18.80
Price to Book
2.01
Price to Sales
5.11
PEG Ratio
0.06
Profitability Ratios
Profit Margin
12.83%
Operating Margin
17.50%
Return on Equity
5.34%
Return on Assets
2.91%
Financial Health
Current Ratio
8.15
Debt to Equity
3.03
Beta
1.96
Per Share Data
EPS (TTM)
$0.82
Book Value per Share
$16.50
Revenue per Share
$6.58
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| VCYT | 2.7B | 40.43 | 2.01 | 5.34% | 12.83% | 3.03 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Revvity | 9.7B | 45.77 | 1.46 | 3.22% | 8.45% | 46.87 |
| Icon plc | 9.0B | 15.52 | 0.94 | 6.27% | 7.40% | 38.26 |
| Charles River | 8.3B | 681.33 | 2.61 | -4.23% | -3.60% | 81.95 |
Financial data is updated regularly. All figures are in the company's reporting currency.





